Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.77 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.60 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.60 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26985759 | 0.96 | SIGMAR1 (0.77) | SIGMAR1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL7360959 | 0.94 | SIGMAR1 (0.81) | SIGMAR1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL7296296 | 0.94 | SIGMAR1 (0.81) | SIGMAR1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL8935187 | 0.94 | SIGMAR1 (0.79) | SIGMAR1 | |
| SCHEMBL27456705 | 0.92 | SIGMAR1 (0.77) | SIGMAR1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL7298415 | 0.92 | SIGMAR1 (0.76) | SIGMAR1 | |
| SCHEMBL1774154 | 0.90 | SIGMAR1 (0.81) | SIGMAR1S1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL536909 | 0.90 | SIGMAR1 (0.73) | SIGMAR1 | |
| SCHEMBL8084220 | 0.89 | SIGMAR1 (0.95) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL6891160 | 0.88 | SIGMAR1 (0.70) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-9328138-B2 | HCV NS3 protease inhibitors | MSD ITALIA S.R.L. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| EP-2780026-A2 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013074386-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-7365174-B2 | Azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1661904-A1 | NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042974-A1 | Nozel azalide and azalactam derivatives and method for producing the same | BCL6, NR4A1, NR4A2 | SIGMAR1 675/4885S1PR2 883/4885S1PR4 313/4885 |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | SIGMAR1 3563/4885S1PR2 4755/4885S1PR4 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.